Plasminogen replacement therapy for plasminogen-deficiency
Subjects of the invention are a method of plasminogen supplementation in a plasminogen-deficient subject, and method for the treatment of plasminogen-deficiency in a plasminogen-deficient subject. These methods comprise administering to the plasminogen-deficient subject a dose of plasminogen, and more particularly Glu-plasminogen, for increasing the subject plasminogen activity level by at least about 1%, and more particularly by at least 10%, of the normal plasminogen activity and for maintaining the plasminogen activity level over a supplementation period or a treatment period. The plasminogen-deficient subject of the present invention may suffer from Type-I, Type-II plasminogen-deficiency or an acquired deficiency.
1. A method for increasing plasminogen activity level in a plasminogen-deficient human subject having a Type I or Type II plasminogen-deficiency, wherein the plasminogen-deficient human subject has a reduced plasmatic plasminogen activity relative to a normal plasmatic plasminogen activity, the method comprising intravenously administering to the plasminogen-deficient human subject a repeated effective dose of Glu-plasminogen over a supplementation period, wherein the repeated effective dose comprises every-two-day, every-three-day, every-four-day or twice-a-week administration at a dose of 1.5 mg/kg to 12 mg/kg of weight of the plasminogen-deficient human subject, and wherein the method increases plasminogen activity level by at least about 10% of the normal plasminogen activity and to a level that is no more than about 300% of the normal plasminogen activity and maintains said increased plasminogen activity level over the supplementation period.
2. The method of claim 1 , wherein the plasminogen-deficient human subject has a Type I plasminogen-deficiency.
3. The method of claim 1 , wherein the plasminogen-deficient human subject has a Type H plasminogen-deficiency.
4. The method of claim 1 , wherein the reduced plasmatic plasminogen activity is less than or equal to about 70% of the normal plasminogen activity.
5. The method of claim 1 , wherein the plasminogen-deficient human subject suffers from ligneous conjunctivitis.
6. The method of claim 1 , wherein the method increases plasminogen activity level by no more than about 150% of the normal plasminogen activity.
7. The method of claim 1 , wherein the method increases plasminogen activity level by no more than about 100% of the normal plasminogen activity.
8. The method of claim 1 , wherein the repeated effective dose comprises every-two-day administration at a dose of −1.5 mg/kg of weight of the plasminogen-deficient human subject.
9. The method of claim 1 , wherein the repeated effective dose comprises twice-a-week administration at a dose of −6 mg/kg of weight of the plasminogen-deficient human subject.
10. The method of claim 1 , wherein the repeated effective dose comprises every-two-day, every-three-day, or every-four-day administration- at a dose of about 6 mg/kg of weight of the plasminogen-deficient human subject.
11. The method of claim 1 , wherein the administered Glu-plasminogen is efficient to i) reduce, treat or prevent a plasminogen-deficiency related lesion, ii) improve an impaired clinical global impression, or iii) improve an impaired quality of life.